The goal of this observational study is to improve cervical pre-cancer treatment outcomes among women living with HIV (WLWH), particularly in low and middle income countries (LMICs), by generating the evidence needed for post-treatment monitoring guidelines. The main questions it aims to answer are: * What is the risk of disease recurrence/persistence after cervical pre-cancer treatment among women living with HIV in Zimbabwe? * What is the predictive value of different human papillomavirus (HPV) and DNA methylation testing strategies for monitoring cervical disease recurrence/persistence after pre-cancer treatment? Participants will have cervical biopsies taken for histological assessment and cervical samples for HPV genotyping and DNA methylation testing. Researchers will follow all participating women every six months for 24 months to evaluate post-treatment monitoring and cervical disease outcomes.
Age range
18 Years – 65 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Cumulative CIN2+ persistence
Timeframe: 6 months
Cumulative CIN2+ persistence
Timeframe: 12 months
Cumulative CIN2+ persistence
Timeframe: 18 months
Cumulative CIN2+ persistence
Timeframe: 24 months
Cumulative CIN2+ persistence among participants with genotype-specific HPV persistence
Timeframe: 24 months
Cumulative CIN2+ persistence among participants with HPV 16 or 18
Timeframe: 24 months
Cumulative CIN2+ persistence among participants with DNA hypermethylation
Timeframe: 24 months
Cumulative CIN2+ persistence among participants with any high-risk HPV
Timeframe: 24 months
Association of baseline factors with CIN2+ persistence
Timeframe: 24 months